

Are your MRI contrast agents cost-effective?
Learn more about generic Gadolinium-Based Contrast Agents.



AJNR

This information is current as
of April 23, 2024.

Radiomics in Brain Tumor: Image Assessment, Quantitative Feature Descriptors, and Machine-Learning Approaches

M. Zhou, J. Scott, B. Chaudhury, L. Hall, D. Goldgof, K.W. Yeom, M. Iv, Y. Ou, J. Kalpathy-Cramer, S. Napel, R. Gillies, O. Gevaert and R. Gatenby

AJNR Am J Neuroradiol 2018, 39 (2) 208-216
doi: <https://doi.org/10.3174/ajnr.A5391>
<http://www.ajnr.org/content/39/2/208>

Radiomics in Brain Tumor: Image Assessment, Quantitative Feature Descriptors, and Machine-Learning Approaches

M. Zhou, J. Scott, B. Chaudhury, L. Hall, D. Goldgof, K.W. Yeom, M. Iv, Y. Ou, J. Kalpathy-Cramer, S. Napel, R. Gillies, O. Gevaert, and R. Gatenby



ABSTRACT

SUMMARY: Radiomics describes a broad set of computational methods that extract quantitative features from radiographic images. The resulting features can be used to inform imaging diagnosis, prognosis, and therapy response in oncology. However, major challenges remain for methodologic developments to optimize feature extraction and provide rapid information flow in clinical settings. Equally important, to be clinically useful, predictive radiomic properties must be clearly linked to meaningful biologic characteristics and qualitative imaging properties familiar to radiologists. Here we use a cross-disciplinary approach to highlight studies in radiomics. We review brain tumor radiologic studies (eg, imaging interpretation) through computational models (eg, computer vision and machine learning) that provide novel clinical insights. We outline current quantitative image feature extraction and prediction strategies with different levels of available clinical classes for supporting clinical decision-making. We further discuss machine-learning challenges and data opportunities to advance radiomic studies.

ABBREVIATIONS: LBP = local binary patterns; HOG = histogram of oriented gradients; QIN = Quantitative Imaging Network; SIFT = scale-invariant feature transform

Clinical imaging captures enormous amounts of information, but most radiologic data are reported in qualitative and subjective terms. Radiomics^{1,2} in neuro-oncology seeks to improve the understanding of the biology and treatment in brain tumors by extracting quantitative features from clinical imaging arrays. These data can then be “mined” with machine-learning methods and validated as quantitative imaging biomarkers³ to characterize intratumoral dynamics throughout the course of treatment. The recent growth of cancer imaging analytic methods^{4–6} has produced novel insights into early indicators of treatment response, risk factors, and subsequent tailoring of optimal treatment strategies.^{2,5,7,8} Image-based computational models are, thus, becoming

an important enabling technology that permits identification, analysis, and validation of extracted quantitative features. In this review, we discuss available methodologies in radiomics that can be used as predictive markers for diagnosis, prognosis, and therapeutic planning in the context of adult brain tumors. We will also address the interpretive challenges that emerge from the computationally based data generated by radiomic methods. While statistical correlations between computational features and clinical outcomes exist, this approach will likely not gain wide clinical acceptance until there is a better link between the quantitative metric and traditional imaging features and the underlying biology.

Radiomics incorporates several important disciplines, including radiology (eg, imaging interpretation), computer vision (eg, quantitative feature extraction), and machine learning (eg, classifier evaluation). A central goal is the identification of quantitative imaging indicators that predict important clinical outcomes, including prognosis and response or resistance to a specific cancer treatment. Here, we discuss recent studies in the development of radiomics with the following goals: 1) understanding the functionality of clinical imaging as a necessary prerequisite for developing radiomic models; 2) extracting quantitative image features extraction in computer vision that can be used to exploit tumor imaging traits; 3) identifying radiomic signatures shown to be surrogate markers of underlying molecular properties of tumors, enabling a noninvasive means to characterize biologic activities of

From the Stanford Center for Biomedical Informatic Research (M.Z., O.G.) and Department of Radiology (K.W.Y., M.I.), Stanford University, Stanford, California; Department of Radiology (J.S., B.C., S.N., R. Gillies, R. Gatenby), Moffitt Cancer Research Center, Tampa, Florida; Department of Computer Science and Engineering (L.H., D.G.), University of South Florida, Tampa, Florida; and Department of Radiology (Y.O., J.K.-C.), Massachusetts General Hospital, Boston, Massachusetts.

This work is supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under award No. R01EB020527.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Please address correspondence to Olivier Gevaert, PhD, Stanford Center for Biomedical Informatics Research, 1265 Welch Rd, Stanford, CA, 94305; e-mail: Olivier.gevaert@stanford.edu; and Robert Gatenby, MD, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612; e-mail: Robert.gatenby@moffitt.org

● Indicates open access to non-subscribers at www.ajnr.org

<http://dx.doi.org/10.3174/ajnr.A5391>

cancer⁹; and 4) performing predictive analysis with machine-learning techniques to classify clinical outcomes and assessing the physiologic status of cancer.¹⁰ Through this convergence of radiology, computer vision, and machine-learning techniques, radiomics provides a mechanism for multidisciplinary research on brain tumors.

Clinical MR Imaging Assessment of Brain Tumors

MR imaging permits noninvasive characterization of mesoscopic features (ie, the “radiologic phenotype”) of brain tumors and is an indispensable tool for early tumor detection, monitoring, and diagnosis.¹¹ Radiomic analysis is built on the central hypothesis that tumor imaging reflects the underlying morphology and dynamics of smaller-scale biologic phenomena, including gene expression patterns, tumor cell proliferation, and blood vessel formation.¹²

MR imaging plays an essential role in the management of patients with glioblastoma for 3 important reasons. First, MR imaging has an excellent capacity for the detection of soft-tissue contrast by providing superior anatomic information (eg, spatial location). Second, different MR imaging sequences can be sensitive to key components of tumor physiology, such as blood flow and cellular density, and can distinguish regions of the tumor that contain different environments (eg, variations in blood flow) that are likely to affect local cellular phenotypes and genotypes. Third, MR imaging can noninvasively and nondestructively interrogate the tumor repeatedly to assess response to treatment and can, therefore, be integrated into therapeutic strategies. Understanding these image-based features is critical because they represent a key data resource in radiomic analysis.¹

Contrast enhancement in MR imaging using gadolinium-based contrast agents is an important and useful feature in evaluating brain tumors.¹³ The tumor zone that enhances following gadolinium injection typically defines the tumor region that is well-perfused with high tumor cell density but also one in which there is a breakdown of the blood-brain barrier. Compared with noncontrast imaging, contrast-enhanced images are often used to provide a delineation of gross tumor margins and allow earlier detection of additional small metastatic lesions. In general, tumor sizes based on these images are used for monitoring tumor response to therapy.¹³ Thus, radiomic models for brain tumor analysis^{14–16} often focus on contrast-enhanced sequences.

Spatial heterogeneity of brain tumors is well-recognized in MR imaging. Different MR imaging sequences exploit various biomedical properties of brain tumors more effectively than other imaging modalities (eg, CT can only show differences in electron density). Postgadolinium T1-weighted images can show enhancing regions (characterized as T1-shortening or T1 high signal) within the tumor due to gadolinium leakage from the intravascular space into the tumor because of a disrupted blood-brain barrier. Consequently, necrosis and solid tumors can be visually distinguished. In addition, T2-weighted sequences are sensitive to water tissue content and can be used to estimate cellular density and the presence of edema. Next, fluid-attenuated inversion-recovery sequences are frequently used in conjunction with T2-weighted images to provide a better distinction between edema and solid tumor.¹⁷ In addition, diffusion-weighted imaging al-

lows characterization of tissue cellularity based on the free diffusion of water molecules along structural tissue pathways in different tissue types.¹⁸ Advanced MR imaging methods, including perfusion, proton density–weighted, fast spin-echo, and short tau inversion-recovery imaging, have also been applied to depict specific tissue contrast.¹⁹ Therefore, mining radiomic data from these advanced imaging arrays will likely offer additional information with respect to tissue discrimination, treatment measurement, and clinical usefulness.

Quantitative Image Feature Extraction

While the quality, resolution, and flexibility of MR imaging technology has greatly increased in past decades, the interpretation of images remains largely descriptive, subjective, and nonquantitative. Thus, the central goal of radiomics is the development of image analytic techniques that can reproducibly extract objective, quantitative data from MR imaging scans. Linking these quantitative features and underlying tissue dynamics that govern tumor growth and response to therapy has the potential to rapidly expand the scope of cancer imaging research.¹ Here, we focus on many related computer vision techniques that are particularly useful in quantitative cancer imaging science.

Computational Image Descriptors

Radiomics relies on computational techniques in computer vision to extract many quantitative features from radiologic images.²⁰ The extracted quantitative features are typically within a defined ROI that could include the whole tumor or specific regions within it. Computational image descriptors quantify visual characteristics at different scales from ROIs, which can be readily translated into radiologic image analysis pertaining to tumor volumetric shapes and visual appearance dynamics. For example, the scale-invariant feature transform (SIFT)^{21,22} is computed through key point detection using a difference of Gaussian function and local image gradient measurement with radius and scale selections (as illustrated in Fig 1). This permits a quantitative measurement of the tumor shape so that subtle variations during treatment (ie, increasingly round or increasingly elliptic) can be observed and quantified. Several recent studies have demonstrated the accuracy and reproducibility of computational image extraction approaches to capture characteristics of tumor shape and texture information from brain tumor MR imaging.^{23–25} Thus, these approaches have the potential for large-scale, rapid throughput and reproducible evaluation and may be applied to routine clinical imaging studies that are widely available.

Here, we describe 2 primary image feature extraction strategies with local- or global-level computations in the context of computer vision. First, local-level feature extraction provides an image descriptor used to compare a pixel being tested with its immediate pixel neighborhood.²⁶ This allows identification of a small, but biologically important, tumor niche area (a small number of pixels) within an otherwise homogeneous, larger tumor region. This can be achieved, for example, with local binary patterns (LBP).²⁷ These are local image descriptors sensitive to small monotonic gray-level differences²⁸ that may not be apparent to a human observer. In contrast, global-level feature extraction em-




FIG 1. Visualization of computational image feature descriptors. A T1-weighted brain tumor section (A and B) is displayed, and feature visualizations (C–E) are given of LBP (C), HOG (D), and SIFT (E) descriptors. LBP quantifies local pixel structures through a binary coding scheme. HOG computes block-wise histogram gradients with multiple orientations. SIFT detects distributed key points with radius on tumor images. These multiparametric features create a rich image-driven data base to characterize tumors in MR imaging at different scales.

Examples of quantitative features with their potential clinical relevance

Quantitative Feature Descriptors	Potential Clinical Relevance
Histogram of contrast-enhanced tumor MRI ⁴⁵	Distinguish molecular subtypes
Contrast information between co-occurring subregions ⁵	Survival predictor
Pretreatment ADC histograms ⁸²	Indicator to bevacizumab treatment
HOG ³⁴	Measure tumor microenvironment
LBP ²⁷	Measure tumor microenvironment
SIFT ²²	Measure tumor spatial characteristics

phasizes the quantification of the overall composition of an entire ROI. For example, a computational descriptor²⁹ was designed to develop a low-dimensional representation of the image, emphasizing spatial structure variations (eg, roughness, openness, and expansion). In addition, high-order statistical features, known as texture features,³⁰ have been widely applied to brain cancer and other cancer imaging analyses.^{14,31} Examples of texture features include gray-level co-occurrence matrices³² and gray-level size zone matrices,³³ which examine the spatial relationships of pixels through a series of statistical measures. Histogram of oriented gradients (HOG)³⁴ features have also proved to be efficient feature descriptors for quantifying image-gradient statistics with multiple directions not obvious to radiologists. A recent study³⁵ suggested that co-occurring gradients in MR imaging were useful for distinguishing brain tumor subtypes.

Despite these advances of computational image descriptors, they may be suboptimal because feature extraction inherently distills a complex dataset of more than a million voxels per MR imaging sequence into a handful of numeric descriptors. To identify a strong radiomic feature, one needs 2 important factors. First, the proposed descriptor must be able to capture distinctive patterns correlated with the clinical outcomes of patients. Moreover, the descriptor must be stable under various image-acquisition parameters. Although MR imaging signals exhibit tumor geometric shapes, appearances, and voxelwise variations with underlying biologic characteristics at molecular, tissue, and organ levels,¹² the potential dynamics and temporal variations in blood flow increase the difficulty in acquiring useful radiomic features. Thus, test-retest and interobserver stability³⁶ are strongly suggested for measuring robust computational image features in radiomic studies. Figure 1 highlights several hand-crafted computational descriptors that capture different visual characteristics of brain tumor MR imaging. Despite the promise of computational image descriptors, the underlying biologic meanings of these features have not been fully exploited, with links to promising therapies and outcome prediction of patients.

Biologically Inspired Feature Descriptor

Biologically inspired feature descriptors build on specific biologic hypotheses that transfer the recognized radiology knowledge into quantitative representation, as opposed to pure computational approaches for feature extraction. Understanding disease characteristics is necessary to propose biologically inspired features because they can be disease-specific.

For example, a recent study³⁷ suggested that MR imaging-derived pharmacokinetic features (eg, extracellular space per unit volume of tissue) were potential biomarkers for separating outcomes of treatment with concurrent radiation therapy and chemotherapy.

Biologically inspired MR imaging features can be used to define organ-level tumor data variation and distribution, offering an opportunity to observe spatial variations and temporal evolution of tumors.¹² For example, a spatial distance measurement³⁸ was defined to quantitatively explore brain tumor heterogeneity. The proposed spatial distances suggested that the variations among biologically defined tumor subregions can reflect distinct prognostic information. Also, early temporal changes and spatial heterogeneity during radiation therapy in heterogeneous regions of high and low perfusion in gliomas might predict different physiologic responses to radiation therapy.³⁹ Other work¹⁶ has proposed a novel concept of imaging habitats that quantifies distinctive tumor subregions by their local contrast enhancement, edema, and cellularity in MR imaging. Moreover, a recent study measured the relationships between MR signal and cell density using radiographically localized biopsies,⁴⁰ revealing that T2-FLAIR and ADC sequences were inversely correlated with cell density. The Table highlights several feature descriptors with their clinical potentials.

Biologically inspired features correlate with corresponding MR imaging sequences because different MR imaging sequences come with various clinical imaging protocols. As a result, selection of MR imaging sequences can directly affect image feature definition and corresponding biologic interpretation. For example, 1 study⁴¹ used apparent diffusion coefficient histograms for the early prediction of drug treatment responses of glioblastomas. In this study, diffusion- and T1-weighted data were used separately for ADC computation and tumor segmentation. The ADC was used to describe the diffusion processes that reflect different




FIG 2. Linking subregional imaging to molecular profiles in glioblastoma. In this example, tumor subregions (*B*) are defined by jointly clustering on contrast-enhanced TIWI and T2WI (*A*). These subregions correspond to red (high TIWI and high T2WI), yellow (high TIWI and low T2WI), blue (low TIWI and high T2WI), and pink (low TIWI and low T2WI) areas. The defined tumor subregions enable quantitative spatial characterization, offering a means to noninvasively assess specific molecular activities (*C*) with enriched molecular pathways (*D*).

biomedical mechanisms.⁴² These biologically inspired features are quantitative rather than qualitative semantic features annotated by radiologists to describe the tumor environment.⁴³ The VASARI semantic feature set (<https://wiki.cancerimagingarchive.net/display/Public/VASARI+Research+Project>), for example, is used to describe the morphology of brain tumors (eg, tumor location, shape, and geometric properties) on contrast-enhanced MR imaging.⁷

Imaging and Genomics in Glioblastoma

Imaging genomics, also known as radiogenomics, is a growing field that studies the association between imaging biomarkers and genomic characteristics of a disease.^{7,44,45} Inherent in this definition is the goal of enabling noninvasive imaging assessment as a surrogate for molecular signatures that were previously only available through molecular testing. A handful of studies^{7,44,45} identified associations between quantitative image features and gene expression profiles of glioblastoma (eg, *TP53*, *EGFR*, *NF1*, and *IDH1*) and its molecular subtypes (eg, classical, mesenchymal, proneural, and neural). Additional studies indicated that quantitative MR imaging features derived from entire tumor volumes can be used to identify glioblastoma subtypes with distinct molecular pathway activities.^{15,46} The value of such whole-tumor comparisons is limited by the spatial variations in both the imaging features and molecular tumor properties of tumor cells in, for example, glioblastoma multiforme. However, this extensive intratumoral heterogeneity also provides a compelling research opportunity if spatial characteristics in MR imaging, largely governed by mesoscopic tumor properties (eg, blood flow and cell density), could be used to define the spatial distribution of glioblastoma molecular subtypes within the same tumor.⁴⁷ To better define imaging-to-genomic relationships, the development of subregional imaging analysis enabling spatial characterization is biologically valuable (Fig 2) because it provides a means to characterize molecular variations in the spatially distinct tumor fragments.

Machine Learning in Radiomics

Machine learning offers an approach for discovering predictive radiomic features. Here, the investigator does not begin with an *a priori* biologic hypothesis. Thus, the parameter space is searched for an imaging feature statistically associated with clinical outcome. Before one evaluates machine-learning models, a specification for the medical diagnostic task is needed so that models can be appropriately trained. For example, supervised, unsupervised, and semisupervised learning models are fundamental learning strategies used in accordance with the different levels of available clinical outcome labels. In supervised learning, the goal is to learn from a certain portion of trained samples with known class labels and to predict classes or numeric values for unknown patterns from large and noisy datasets.⁴⁷ Conversely, unsupervised learning finds the natural structure from data without having any prior labels. As a hybrid setting, semisupervised learning needs only a small portion of labeled training data. The unlabeled data samples, instead of being discarded, are also used in the learning process. More recently, the rise of deep learning as a new frontier in machine learning has advanced large-scale medical image analysis.⁴⁸ We describe these learning strategies and highlight specific clinical applications in the context of brain tumors.

Supervised Learning

Supervised learning is a primary learning scheme that has been applied in recent radiomic studies.^{16,23} Supervised learning is conceptually divided into 2 phases. First, training samples with available class labels are used to build a classifier by finding a set of parameters to define a decision boundary among classes. Second, the learned classifier is used to predict class labels of unknown testing samples. Notably, the selection of classifiers depends on the desired properties of the classifier, including convergence and modeling assumptions.⁴⁹ An example of this approach is a study⁵⁰ that showed the selection of machine-learning classifiers for supervised radiomic applications in detecting radiomic biomarkers. More examples include tumor-subtype classification and survival

time prediction, and these are discussed in clinical applications below.

Unsupervised Learning

Without knowing any prior labels of data, unsupervised learning algorithms group the data according to their similarity. For example, a knowledge-based unsupervised fuzzy clustering approach⁵¹ was proposed to automate brain tumor segmentation. It showed that tumor and healthy intracranial regions could be grouped using this clustering algorithm through a rule-based expert system. The growth of clinical imaging results in the onerous task of manually annotating tumors on imaging volumes. Therefore, there has been growing interest in exploring scalable algorithms for annotating large volumes of tumor imaging data¹⁵ and evaluating human interrater variability.⁵²

Semisupervised Learning

Semisupervised learning is designed specifically for tasks for which it is difficult to obtain class labels for certain patients (eg, the estimation of tumor progression). In other words, the advance of semisupervised learning overcomes a limitation of conventional supervised learning that is incapable of using data with missing labels in training. Semisupervised models have a great potential to effectively enable predictive analysis with uncompleted clinical labels in training. For example, 1 study⁵³ predicted states of brain tumor prognosis using a semisupervised learning model. With <26% of the available staging labels, a discriminative analysis was performed using the staging labels of patients with glioblastoma.

Deep Learning

Recently, deep learning^{54,55} has emerged as a powerful technique that defines a network architecture, concatenating multiple neural-like processing layers with multiple levels of abstraction. Deep learning methods have achieved record-breaking performances for numerous computer vision applications when the number of available training samples is sufficiently large.⁵⁶ Convolutional neural networks,⁵⁷ for example, are deep learning models that incorporate concatenated convolutional layers and pooling layers, followed by fully connected layers to learn the high-level representation of input data. A growing set of studies has shown superior results in the field of medical image analysis by applying convolutional neural networks models.^{48,58-60} A recent study⁶¹ specifically introduced a convolutional neural networks-based approach for brain tumor segmentation. With the designed network architecture containing multiple small 3×3 kernels and deep layers, the model achieved strong segmentation performance (DICE score = 0.88) on the Brain Tumor Segmentation Challenge 2013 data base (<http://braintumorsegmentation.org/>).

Specific Clinical Applications of Radiomics

Survival Time Prediction. Predicting prognostic performance of glioblastomas using clinical imaging alone is challenging due to the radiographic heterogeneity of tumors. Stratification of clinical groups will directly impact image-guided diagnosis and targeted treatment.¹⁶ In contrast to qualitative assessment (enhancing tumor, edema, and multifocal lesions)⁶² made by radiologists, a

recent study⁵ introduced quantitative spatial imaging biomarkers to predict survival time for patients with glioblastomas. Such work requires a labeled training set with survival information. It suggested that contrast information gained from co-occurring subregions on FLAIR and T2-weighted images was useful to separate long-term (>400 days) and short-term (<400 days) survival groups.

Classification of Glioblastoma Subtypes. An example of the classification of brain tumor histologic groups²⁵ demonstrated the usefulness of radiomic features to rapidly classify gliomas, metastases, and high- (grade III and grade IV) and low-grade (grade II) neoplasms. The quantitative image analysis collected brain tumor identification, raw intensity values, and MR imaging-based texture features to demonstrate the capability of multiparametric MR imaging features to separate histologic classes of brain tumors. In addition, a recent study⁴⁵ showed the possibility of classifying molecular subtypes of glioblastomas using radiomic features alone. In this approach, histograms of MR imaging intensity in enhanced tumors were identified to provide added value for predicting molecular subtypes of glioblastoma.⁴⁵

Tumor–Tissue Discriminative Analysis. Differentiating radiation necrosis from tumor recurrence is difficult in patients with glioblastoma undergoing chemoradiation because traditional qualitative interpretation of conventional contrast-enhanced MR imaging is unlikely to differentiate chemoradiation-induced necrosis and pseudoprogression.⁶³ By contrast, quantitative MR imaging features⁶⁴ were shown to differentiate radiation necrosis from recurrent tumor. Results revealed that a set of quantitative intensity features obtained from multiple MR imaging arrays (eg, T1, T2, relative CBF, and ADC) was useful for detecting radiation necrosis tissue in resected patients with glioblastoma multiforme undergoing chemoradiation.

Research Opportunities and Challenges

Substantial progress has been made from recent radiomic studies to deepen our understanding of imaging characteristics in cancer.^{1,2} The identified quantitative features can be used to alert radiologists to suspicious abnormalities because radiomic models can even capture subtle variations in tumor environment not easily perceived by human experts. We highlighted the convergence of quantitative image feature extraction and machine-learning techniques for supporting diagnosis, prognosis, and treatment predictions. Next, we discuss challenges and opportunities that are not only related to brain tumor MR imaging but also applicable to other types of cancer studies in radiomics.

Development of Treatment-Specific Radiomics

There is a growing need to develop radiomic signatures that can be used to directly inform specific treatment options. With diffusion-weighted MR imaging, emerging evidence revealed that ADC maps were useful to differentiate treatment outcomes in glioblastoma with radiation therapy concurrent with temozolamide.⁶⁵ Also, early changes of ADC maps were identified for predicting glioblastoma recurrence.⁶⁶ In addition, a decrease in the volume of FLAIR signal and contrast enhancement⁶⁷ was shown to predict the response to bevacizumab treatment for patients




FIG 3. Illustration of the convolutional neural networks model using imaging and other biomedical data for brain tumor analysis. The convolutional neural networks model consists of multiple convolutional layers, pooling layers, and fully connected layers to learn an abstraction of the input data, such as imaging and clinical features for a variety of outcome evaluations.

with glioblastomas. To better understand the biologic implications of these imaging findings, the collection of temporal imaging at multiple diagnostic periods will offer an opportunity to consistently characterize biologic tumor evolution before and after treatment.⁶⁸ Currently, distinguishing tumor response between pseudoprogression and pseudoresponse continues to be challenging in tumor MR imaging⁶⁹; thus, development of radiomic features to contribute to treatment outcome analysis will be appealing. Although the type of radiomic features that will eventually be validated as true predictors responsive to different treatments is still to be determined, the vast quantity of radiomic findings, in conjunction with the growth of molecular data, will increase the possibility of a redefinition of tumor subtypes and novel biomarker discovery to inform treatment decisions in the coming years.

Machine Learning

Extracting large-scale radiomic features from a variety of imaging arrays creates a rich data base containing clinically relevant information. Both computational and biologically inspired feature descriptors are important and useful for machine learning. Thus, development of scalable machine-learning techniques is vital to search for and identify useful image features associated with outcome variables and clinical records. We discuss 2 representative techniques to address this need. First, a suggested approach is to investigate sparse-learning models, also known as lasso regularization,⁷⁰ for finding a useful set of reduced features from a high-dimensional feature vector. Emerging evidence suggests that sparse learning is useful for identifying multiparametric prognostic imaging biomarkers in non–small cell lung cancer.⁷¹

Second, recent breakthroughs in deep learning with applications in radiology, such as lung nodule malignancy classification^{58,59} and lymph node detection,⁷² have been encouraging in finding disease-specific imaging biomarkers. However, the availability of labeled medical data poses a challenge for developing efficient deep-learning models. For example, cancer images with pathologically proved labels are costly to collect at scale; thus, data integration with different types of clinical labels may present an alternative means to overcome such obstacles for deep-learning models, which need large datasets as input.⁷³ Although how we gain clinical insight from these deep-learning outcomes and how

we optimize network architectures for the better use of multiscale medical data (eg, serial MR imaging, genomics, and clinical data) are uncertain,⁷⁴ the extraction of compact patterns via hierarchical networks presents enormous opportunities for large-scale radiomic applications (Fig 3).

The Role of Radiomics in Big Data

Radiomic studies follow the theme of emerging big data in health care that concerns mining vast quantities of biomedical data.^{75,76} A typical concern of radiomics in big data relates to the management of growing image data, gene expression profiles, and the associated clinical records. Multiple data sources (eg, medical institutions) and various data types (eg, multitechnique imaging data) make data sharing and collective administration an especially complex problem. Enabling data standardization across different image protocols and parameters becomes a prerequisite for collective study. The pilot project of the Cancer Genome Atlas⁷⁷ is an initiative to provide a large portion of clinical data and generic information. As a parallel effort, The Cancer Imaging Archive⁴ is growing rapidly for sharing radiologic images. Also, the Quantitative Imaging Network⁷⁸ is designed to promote efficient data integration that helps validate imaging biomarkers that are impactful in treating cancer. More recently, MR fingerprinting⁷⁹ was introduced to advance the role of quantitative MR imaging using pseudorandomized acquisition parameters. However, large-scale, high-quality benchmark datasets, including complete clinical labels, standard radiomic features, and molecular profiles, are not widely available for data sharing, experimental evaluation, and reproducibility of radiomics toward precision medicine.^{80,81}

CONCLUSIONS

The rapid discovery rate of novel imaging biomarkers in radiomics allows integrating information from interdisciplinary approaches in radiology, computer vision, and machine learning. With the growth of clinical imaging data, novel image-based computational models are playing an increasingly important role for precise diagnosis and treatment guidance in neuro-oncology. Only when these models align well with tumor biology will radiomic findings maximize their likelihood for clinical utility. Research challenges remain for exploring cancer heterogeneity, scalable computational models, and the clinical significance of

radiomic findings. We believe that the newly emerging diagnostic hypotheses and scalable machine-learning algorithms have the potential for enhancing the current performance of predictive cancer diagnosis and accelerating quantitative cancer imaging findings to reach their true clinical potential.

Disclosures: Mu Zhou—**RELATED:** *Grant:* National Institutes of Health, *Comments:* National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under award No. R01EB020527. Jayashree Kalpathy-Cramer—**RELATED:** *Grant:* National Institutes of Health, *Comments:* National Institutes of Health/National Cancer Institute U24CA180927, National Institutes of Health/National Cancer Institute U24CA180918, National Institutes of Health/National Cancer Institute U01CA154601*; *Consulting Fee or Honorarium:* Infotech Software, *Comments:* amount of <\$2000. Sandy Napel—**UNRELATED:** *Board Membership:* EchoPixel, Fovia, Radlogics, *Comments:* scientific advisory boards; *Consultancy:* Algotec. Robert Gillies—**RELATED:** *Grant:* National Institutes of Health*, **UNRELATED:** *Stock/Stock Options:* HealthMyne, *Comments:* a radiomics PACS system not used in the current article. Olivier Gevaert—**RELATED:** *Grant:* National Institutes of Health*, *Comments:* National Institutes of Health No. R01EB020527; **UNRELATED:** *Grants/Grants Pending:* National Institutes of Health*. *Money paid to the institution.

REFERENCES

1. Gillies RJ, Kinahan PE, Hricak H. **Radiomics: images are more than pictures, they are data.** *Radiology* 2016;278:563–77 CrossRef Medline
2. Kumar V, Gu YH, Basu S, et al. **Radiomics: the process and the challenges.** *Magn Reson Imaging* 2012;30:1234–48 CrossRef Medline
3. Ludwig JA, Weinstein JN. **Biomarkers in cancer staging, prognosis and treatment selection.** *Nat Rev Cancer* 2005;5:845–56 CrossRef Medline
4. Prior FW, Clark K, Commean P, et al. **TCIA: an information resource to enable open science.** In: *Proceedings of the 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society*, Osaka, Japan. July 3–7, 2013;1282–85
5. Zhou M, Chaudhury B, Hall LO, et al. **Identifying spatial imaging biomarkers of glioblastoma multiforme for survival group prediction.** *J Magn Reson Imaging* 2016;46:115–23
6. Aerts HJ, Velazquez ER, Leijenaar RTH, et al. **Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.** *Nat Commun* 2014;5:4006 CrossRef Medline
7. Gutman DA, Cooper LA, Hwang SN, et al. **MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set.** *Radiology* 2013;267:560–69 CrossRef Medline
8. Kotrotsou A, Zinn PO, Colen RR. **Radiomics in brain tumors: an emerging technique for characterization of tumor environment.** *Magn Reson Imaging Clin North Am* 2016;24:719–29 CrossRef Medline
9. Jaffe CC. **Imaging and genomics: is there a synergy?** *Radiology* 2012; 264:329–31 CrossRef Medline
10. Michaelis LC, Ratain MJ. **Measuring response in a post-RECIST world: from black and white to shades of grey.** *Nat Rev Cancer* 2006; 6:409–14 CrossRef Medline
11. Kheifets LI. **Electric and magnetic field exposure and brain cancer: a review.** *Bioelectromagnetics* 2001;(suppl 5):S120–31 Medline
12. Gatenby RA, Grove O, Gillies RJ. **Quantitative imaging in cancer evolution and ecology.** *Radiology* 2013;269:8–15 CrossRef Medline
13. Drevelegas A, Papanikolaou N. **Imaging modalities in brain tumors.** In: Drevelegas A. *Imaging of Brain Tumors with Histological Correlations*. Berlin: Springer; 2011:13–33
14. Kickingereder P, Götz M, Muschelli J, et al. **Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response.** *Clin Cancer Res* 2016;22:5765–71 CrossRef Medline
15. Itakura H, Achrol AS, Mitchell LA, et al. **Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities.** *Sci Transl Med* 2015;7:303ra138 CrossRef Medline
16. Zhou M, Hall L, Goldgof D, et al. **Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results.** *Transl Oncol* 2014;7:5–13 CrossRef Medline
17. Tsuchiya K, Inaoka S, Mizutani Y, et al. **Fast fluid-attenuated inversion-recovery MR of intracranial infections.** *AJNR Am J Neuroradiol* 1997;18:909–13 Medline
18. Padhani AR, Liu G, Koh DM, et al. **Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.** *Neoplasia* 2009;11:102–25 CrossRef Medline
19. Bitar R, Leung G, Perng R, et al. **MR pulse sequences: what every radiologist wants to know but is afraid to ask.** *Radiographics* 2006; 26:513–37 CrossRef Medline
20. Lambin P, Rios-Velazquez E, Leijenaar R, et al. **Radiomics: extracting more information from medical images using advanced feature analysis.** *Eur J Cancer* 2012;48:441–46 CrossRef Medline
21. Ambrosini RD, Wang P, O'Dell WG. **Computer-aided detection of metastatic brain tumors using automated three-dimensional template matching.** *J Magn Reson Imaging* 2010;31:85–93 CrossRef Medline
22. Lowe DG. **Object recognition from local scale-invariant features.** In: *Proceedings of the Seventh IEEE International Conference on Computer Vision*, Corfu, Greece. September 20–25, 1999;1150–57
23. Zikic D, Glocker B, Konukoglu E, et al. **Decision forests for tissue-specific segmentation of high-grade gliomas in multi-channel MR.** In: Ayache N, Delingette H, Golland P, et al, eds; *Medical Image Computing and Computer-Assisted Intervention—MICCAI* 2012. Berlin: Springer; 2012:369–76
24. Reddy KK, Solmaz B, Yan P, et al. **Confidence guided enhancing brain tumor segmentation in multi-parametric MRI.** In: *Proceedings of the 9th IEEE International Symposium on Biomedical Imaging*, Barcelona, Spain. May 2–5, 2012:366–69
25. Zacharaki EI, Wang S, Chawla S, et al. **Classification of brain tumor type and grade using MRI texture and shape in a machine learning scheme.** *Magn Reson Med* 2009;62:1609–18 CrossRef Medline
26. Tuytelaars T, Mikolajczyk K. **Local invariant feature detectors: a survey.** *Foundations and Trends in Computer Graphics and Vision* 2008;3:177–280
27. Ojala T, Pietikäinen M, Mäenpää T. **Multiresolution gray-scale and rotation invariant texture classification with local binary patterns.** *IEEE Transactions on Pattern Analysis and Machine Intelligence* 2002; 24:971–87 CrossRef
28. Heikkilä M, Pietikäinen M, Schmid C. **Description of interest regions with local binary patterns.** *Pattern Recognition* 2009;42:425–36 CrossRef
29. Oliva A, Torralba A. **Modeling the shape of the scene: a holistic representation of the spatial envelope.** *International Journal of Computer Vision* 2001;42:145–75 CrossRef
30. Kassner A, Thornhill RE. **Texture analysis: a review of neurologic MR imaging applications.** *AJNR Am J Neuroradiol* 2010;31:809–16 CrossRef Medline
31. Aerts HJ, Velazquez ER, Leijenaar RT, et al. **Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.** *Nat Commun* 2014;5:4006 CrossRef Medline
32. Haralick RM, Shanmugam K, Dinstein I. **Textural features for image classification.** *IEEE Transactions on Systems Man Cybernetics* 1973;Smc3:610–21
33. Galloway MM. **Texture analysis using gray level run lengths.** *Computer Graphics and Image Processing* 1975;4:172–79 CrossRef
34. Dalal N, Triggs B. **Histograms of oriented gradients for human detection.** In: *Proceedings of the 2005 IEEE Computer Society Conference on Computer Vision and Pattern Recognition*, San Diego, California. June 20–26, 2005:886–93
35. Prasanna P, Tiwari P, Madabhushi A. **Co-occurrence of Local Anisotropic Gradient Orientations (CoLiAGE): distinguishing tumor confounders and molecular subtypes on MRI.** In: Ayache N, Delingette H, Golland P, et al, eds. *Medical Image Computing and Computer-Assisted Intervention—MICCAI* 2012. Berlin: Springer; 2012:369–76
36. Leijenaar RT, Carvalho S, Velazquez ER, et al. **Stability of FDG-PET**

- radiomics features: an integrated analysis of test-retest and inter-observer variability.** *Acta Oncol* 2013;52:1391–97 CrossRef Medline
37. Yun TJ, Park CK, Kim TM, et al. **Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.** *Radiology* 2015;274: 830–40 CrossRef Medline
 38. Zhou M, Hall LO, Goldgof DB, et al. **Survival time prediction of patients with glioblastoma multiforme tumors using spatial distance measurement.** *SPIE Proceedings* 2013;8670:86702O CrossRef
 39. Cao Y, Tsien CI, Nagesh V, et al. **Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT.** *Int J Radiat Oncol Biol Phys* 2006;64:876–85 CrossRef Medline
 40. Chang PD, Malone HR, Bowden SG, et al. **A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies.** *AJNR Am J Neuroradiol* 2017;38:890–98 CrossRef Medline
 41. Huo J, Kim HJ, Pope WB, et al. **Histogram-based classification with Gaussian mixture modeling for GBM tumor treatment response using ADC map.** *SPIE Proceedings* 2009;7260:72601Y CrossRef
 42. Le Bihan D, Breton E, Lallemand D, et al. **MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders.** *Radiology* 1986;161:401–07 CrossRef Medline
 43. Mazurowski MA, Desjardins A, Malof JM. **Imaging descriptors improve the predictive power of survival models for glioblastoma patients.** *Neuro Oncol* 2013;15:1389–94 CrossRef Medline
 44. Zinn PO, Mahajan B, Majadan B, et al. **Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme.** *PLoS One* 2011;6:e25451 CrossRef Medline
 45. Macyszyn L, Akbari H, Pisapia JM, et al. **Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.** *Neuro Oncol* 2016;18:417–25 CrossRef Medline
 46. Gevaert O, Mitchell LA, Achrol AS, et al. **Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features.** *Radiology* 2014;273:168–74 CrossRef Medline
 47. Cruz JA, Wishart DS. **Applications of machine learning in cancer prediction and prognosis.** *Cancer Inform* 2007;2:59–77 Medline
 48. Shen D, Wu G, Suk HI. **Deep learning in medical image analysis.** *Annu Rev Biomed Eng* 2017;19:221–48 CrossRef Medline
 49. Mitchell T. The discipline of machine learning. Carnegie Mellon University, School of Computer Science, Machine Learning Department; 2006. <http://docplayer.net/19055685-The-discipline-of-machine-learning.html>. Accessed September 26, 2017
 50. Parmar C, Grossmann P, Bussink J, et al. **Machine learning methods for quantitative radiomic biomarkers.** *Sci Rep* 2015;5:13087 CrossRef Medline
 51. Clark MC, Hall LO, Goldgof DB, et al. **Automatic tumor segmentation using knowledge-based techniques.** *IEEE Trans Med Imaging* 1998;17:187–201 CrossRef Medline
 52. Menze BH, Jakab A, Bauer S, et al. **The multimodal Brain Tumor Image Segmentation Benchmark (BRATS).** *IEEE Trans Med Imaging* 2015;34:1993–2024 CrossRef Medline
 53. Cruz-Barbosa R, Vellido A. **Semi-supervised analysis of human brain tumours from partially labeled MRS information, using manifold learning models.** *Int J Neural Syst* 2011;21:17–29 CrossRef Medline
 54. LeCun Y, Bengio Y, Hinton G. **Deep learning.** *Nature* 2015;521: 436–44 CrossRef Medline
 55. Szegedy C, Liu W, Jia YQ, et al. **Going deeper with convolutions.** In: *Proceedings of the 2009 IEEE Conference on Computer Vision and Pattern Recognition*, Miami, Florida. June 20–25, 2015;1–9
 56. Deng J, Dong W, Socher R, et al. **ImageNet: a large-scale hierarchical image database.** In: *Proceedings of the 2009 IEEE Conference on Computer Vision and Pattern Recognition*, Miami, Florida. June 20–25, 2015;248–55
 57. Karpathy A, Toderici G, Shetty S, et al. **Large-scale video classification with convolutional neural networks.** In: *Proceedings of the 2014 IEEE Conference on Computer Vision and Pattern Recognition*, Columbus, Ohio. June 23–28, 2014;1725–32
 58. Shen W, Zhou M, Yang F, et al. **Multi-scale convolutional neural networks for lung nodule classification.** *Inf Process Med Imaging* 2015;24:588–99 Medline
 59. Shen W, Zhou M, Yang F, et al. **Multi-crop convolutional neural networks for lung nodule malignancy suspiciousness classification.** *Pattern Recognition* 2017;61:663–73 CrossRef
 60. Setio AA, Ciompi F, Litjens G, et al. **Pulmonary nodule detection in CT images: false positive reduction using multi-view convolutional networks.** *IEEE Trans Med Imaging* 2016;35:1160–69 CrossRef Medline
 61. Pereira S, Pinto A, Alves V, et al. **Brain tumor segmentation using convolutional neural networks in MRI images.** *IEEE Trans Med Imaging* 2016;35:1240–51 CrossRef Medline
 62. Pope WB, Sayre J, Perlina A, et al. **MR imaging correlates of survival in patients with high-grade gliomas.** *AJNR Am J Neuroradiol* 2005; 26:2466–74 Medline
 63. Siu A, Wind JJ, Iorgulescu JB, et al. **Radiation necrosis following treatment of high grade glioma: a review of the literature and current understanding.** *Acta Neurochir (Wien)* 2012;154:191–201; discussion 201 CrossRef Medline
 64. Hu X, Wong KK, Young GS, et al. **Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma.** *J Magn Reson Imaging* 2011;33:296–305 CrossRef Medline
 65. Chu HH, Choi SH, Ryoo I, et al. **Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolamide: comparison study of standard and high-b-value diffusion-weighted imaging.** *Radiology* 2013;269:831–40 CrossRef Medline
 66. Chang PD, Chow DS, Yang PH, et al. **Predicting glioblastoma recurrence by early changes in the apparent diffusion coefficient value and signal intensity on FLAIR images.** *AJR Am J Roentgenol.* 2017; 208:57–65 CrossRef Medline
 67. Ellingson BM, Cloughesy TF, Lai A, et al. **Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab.** *Neuro Oncol* 2011;13:401–09 CrossRef Medline
 68. Zhou M, Hall LO, Goldgof DB, et al. **Decoding brain cancer dynamics: a quantitative histogram-based approach using temporal MRI.** *SPIE Proceedings* 2015;9414
 69. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, et al. **Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.** *AJNR Am J Neuroradiol* 2011;32: 1978–85 CrossRef Medline
 70. Tibshirani R. **Regression shrinkage and selection via the lasso.** *Journal of the Royal Statistical Society. Series B (Methodological)* 1996;58:267–88
 71. Gevaert O, Xu J, Hoang CD, et al. **Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data—methods and preliminary results.** *Radiology* 2012;264:387–96 CrossRef Medline
 72. Shin HC, Roth HR, Gao MC, et al. **Deep convolutional neural networks for computer-aided detection: CNN architectures, dataset characteristics and transfer learning.** *IEEE Trans Med Imaging* 2016; 35:1285–98 CrossRef Medline
 73. Shen W, Zhou M, Yang F, et al. **Learning from experts: developing transferable deep features for patient-level lung cancer prediction.** In: *Proceedings of the 19th Medical Image Computing and Computer-Assisted Intervention Conference*, Athens, Greece. October 17–21, 2016;124–31
 74. Mamoshina P, Vieira A, Putin E, et al. **Applications of deep learning in biomedicine.** *Mol Pharm* 2016;13:1445–54 CrossRef Medline
 75. Manyika J, Chui M, Brown B, et al. Big data: the next frontier for innovation, competition, and productivity. McKinsey Global Institute. 2011. <http://www.mckinsey.com/business-functions/digital-mckinsey/our-insights/big-data-the-next-frontier-for-innovation>. Accessed September 26, 2017

76. Bates DW, Saria S, Ohno-Machado L, et al. **Big data in health care: using analytics to identify and manage high-risk and high-cost patients.** *Health Aff (Millwood)* 2014;33:1123–31 CrossRef Medline
77. Cancer Genome Atlas Research Network. **Comprehensive genomic characterization defines human glioblastoma genes and core pathways.** *Nature* 2008;455:1061–68 CrossRef Medline
78. Kalpathy-Cramer J, Freymann JB, Kirby JS, et al. **Quantitative imaging network: data sharing and competitive algorithm validation leveraging The Cancer Imaging Archive.** *Transl Oncol* 2014;7:147–52 CrossRef Medline
79. Badve C, Yu A, Dastmalchian S, et al. **MR fingerprinting of adult brain tumors: initial experience.** *AJNR Am J Neuroradiol* 2017;38:492–99 CrossRef Medline
80. Aerts HJ. **The potential of radiomic-based phenotyping in precision medicine: a review.** *JAMA Oncol* 2016;2:1636–42 CrossRef Medline
81. O'Connor JP, Aboagye EO, Adams JE, et al. **Imaging biomarker roadmap for cancer studies.** *Nat Rev Clin Oncol* 2017;14:169–86 CrossRef Medline
82. Ellingson B, Sahebjam S, Kim HJ, et al. **Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.** *AJNR Am J Neuroradiol* 2014;35:673–79 CrossRef Medline